FDA safety policy post
Executive Summary
Director of FDA's Office of Pharmacoepidemiology & Statistical Science Paul Seligman will serve as the agency's new associate director for safety policy & communications starting in mid-May. One area of focus for the new associate director will be the implementation of an FDA drug safety bulletin that will be distributed to the public on a regular basis. He also will oversee the Drug Safety Oversight Board and the MedWatch program. Seligman's former position is being eliminated as part of an agency reorganization (1"The Pink Sheet" Nov. 7, 2005, p. 3)...
You may also be interested in...
FDA Interaction With Health Professionals To Get Boost From New Office
FDA is in the preliminary stages of developing an office of health professionals to handle the agency's interaction with professional societies
FDA’s Drug Center Reorganization Creates Second Safety Director Position
The Center for Drug Evaluation & Research will divide its drug safety functions between a new associate center director and its existing Office of Drug Safety
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.